CONCORD, Calif.--(BUSINESS WIRE)--
Cerus Corporation (Nasdaq: CERS) today announced the appointment of Eric
Bjerkholt to its Board of Directors. Mr. Bjerkholt currently serves as
the chief financial officer of Aimmune Therapeutics, a San Francisco Bay
Area biopharmaceutical company focused on the development of treatments
to help protect people with food allergies. Mr. Bjerkholt brings over
three decades of healthcare and biotech leadership experience to the
Cerus Board, which has now been expanded to eight members.
“We are pleased to welcome Eric to Cerus’ Board of Directors,” said
Daniel Swisher, Chair of the Board. “Eric is an accomplished healthcare
executive with extensive experience in financial strategy, business
development, and operations. Eric’s addition provides another valuable
perspective on key factors that are critical to our future success.”
“Cerus is redefining blood safety and availability to the potential
benefit of millions of patients around the globe,” said Mr. Bjerkholt.
“It is an exciting time and I’m looking forward to working with the
Company to achieve a new standard of care in transfusion medicine.”
Prior to joining Aimmune Therapeutics in 2017, Mr. Bjerkholt served as
the chief financial officer of Sunesis Pharmaceuticals Inc., where,
during his 13 years with the company, he oversaw all aspects of finance,
business development, governance, and corporate relations. Prior to
Sunesis, Mr. Bjerkholt was the chief financial officer of IntraBiotics
Pharmaceuticals, Inc. and LifeSpring Nutrition, Inc. Mr. Bjerkholt began
his healthcare career in investment banking at J.P. Morgan.
Mr. Bjerkholt currently serves on the board and is the chair of the
audit committee of Corium International, Inc., a publicly traded,
commercial stage biopharmaceutical company focused on the development of
transdermal drug delivery products.
ABOUT CERUS
Cerus Corporation is a biomedical products company focused in the field
of blood transfusion safety. The INTERCEPT Blood System is designed to
reduce the risk of transfusion-transmitted infections by inactivating a
broad range of pathogens such as viruses, bacteria and parasites that
may be present in donated blood. The nucleic acid targeting mechanism of
action of the INTERCEPT treatment is designed to inactivate established
transfusion threats, such as hepatitis B and C, HIV, West Nile virus and
bacteria, as well as emerging pathogens such as chikungunya, malaria and
dengue. Cerus currently markets and sells the INTERCEPT Blood System for
both platelets and plasma in the United States, Europe, the Commonwealth
of Independent States, the Middle East and selected countries in other
regions around the world. The INTERCEPT Red Blood Cell system is in
clinical development. See http://www.cerus.com
for information about Cerus.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20181009005938/en/
Cerus Corporation
Tim Lee, 925-288-6137
Investor Relations
Director
Source: Cerus Corporation